Retatrutide Research

What Does "Reta" Mean?

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library1 min readLast reviewed 2026-08-233 cited sources

The short answer

Reta is informal shorthand for retatrutide. The full name follows WHO International Nonproprietary Name conventions: the -tide suffix denotes a peptide, and the preceding stem identifies its pharmacological class, -glutide marks a GLP-1 analogue, while -trutide marks the multi-receptor incretin agonists that retatrutide and tirzepatide belong to.

Key facts

Reta
Informal shorthand
Full INN
Retatrutide
Development code
LY3437943
-tide suffix
Denotes a peptide
-glutide stem
GLP-1 analogues
-trutide stem
Multi-receptor incretin agonists

How INN names are built

The WHO assigns International Nonproprietary Names using standardised stems that encode pharmacology. The suffix -tide marks a peptide. Within that, -glutide identifies GLP-1 analogues, which is why semaglutide, liraglutide and dulaglutide share it. Retatrutide and tirzepatide carry -trutide, marking the multi-receptor incretin agonists.

Why the naming system is useful

An unfamiliar drug name in a paper still tells you something. Anything ending -glutide is a GLP-1 analogue peptide. Anything ending -tide is a peptide at all. The stems are deliberately informative, which makes the system worth knowing rather than merely tolerating.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

INN versus development code

LY3437943 is Lilly's internal designation and appears in trial registrations and the discovery literature. Retatrutide is the INN, assigned as the compound progressed. Both refer to the same molecule, and searching both surfaces different records. The code finds earlier work, the INN finds later.

What an INN does not signify

Approval. An INN is assigned so a compound has one unambiguous generic name; it says nothing about regulatory status. DSIP holds an INN, emideltide, and is approved nowhere. Retatrutide holds one and is likewise approved nowhere.

Why the shorthand exists

Retatrutide is a mouthful, and abbreviated forms circulate in informal discussion. Reta carries no technical meaning and appears in no scientific literature. Searching for it finds forum and commercial content rather than research, in the same way TB-500 does.

Frequently asked questions

What does the -tide suffix mean?

That the compound is a peptide. Within that, -glutide marks GLP-1 analogues and -trutide marks multi-receptor incretin agonists.

Is reta used in scientific literature?

No. It is informal shorthand. Papers use retatrutide or the development code LY3437943.

Does having an INN mean it is approved?

No. An INN is a naming decision. DSIP holds one and is approved nowhere; so is retatrutide.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More Retatrutide Research articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.